Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/141453
Registo completo
Campo DCValorIdioma
dc.creatorBatista, R
dc.creatorVinagre, N
dc.creatorMeireles, S
dc.creatorVinagre, J
dc.creatorPrazeres, H
dc.creatorLeão, R
dc.creatorMáximo, V
dc.creatorSoares, P
dc.date.accessioned2022-06-27T10:35:17Z-
dc.date.available2022-06-27T10:35:17Z-
dc.date.issued2020
dc.identifier.issn2075-4418
dc.identifier.urihttps://hdl.handle.net/10216/141453-
dc.description.abstractBladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is a complex disease with several molecular and pathological pathways, thus reflecting different behaviors depending on the clinical staging of the tumor and molecular type. Diagnosis and monitoring of BC is mainly performed by invasive tests, namely periodic cystoscopies; this procedure, although a reliable method, is highly uncomfortable for the patient and it is not exempt of comorbidities. Currently, there is no formal indication for the use of molecular biomarkers in clinical practice, even though there are several tests available. There is an imperative need for a clinical non-invasive testing for early detection, disease monitoring, and treatment response in BC. In this review, we aim to assess and compare different tests based on molecular biomarkers and evaluate their potential role as new molecules for bladder cancer diagnosis, follow-up, and treatment response monitoring.
dc.description.sponsorshipThis research was funded by FCT ("Portuguese Foundation for Science and Technology") through a PhD grant to R.B. (SFRH/BD/111321/2015). Further funding was obtained from the project "Advancing cancer research: from basic knowledge to application" NORTE-01-0145-FEDER-000029: "Projetos Estruturados de I & D & I," funded by Norte 2020 - Programa Operacional Regional do Norte. This article is also a result of the project PTDC/MED-ONC/31438/2017 (The Other Faces of Telomerase: Looking beyond Tumor Immortalization), supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), COMPETE 2020?Operacional Programme for Competitiveness and Internationalisation (POCI) and by Portuguese funds through FCT. The APC was funded by the European Regional Development Fund (ERDF) through the Operational Programme for Competitiveness and Internationalisation?COMPETE 2020, and Portuguese national funds via FCT, under project POCI-01-0145-FEDER-016390: CANCEL STEM.
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_NORTE/SFRH%2FBD%2F111321%2F2015/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC%2FMED-ONC%2F31438%2F2017/PT
dc.relation.ispartofDiagnostics, vol.10(1):39
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleBiomarkers for bladder cancer diagnosis and surveillance: A comprehensive review
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/diagnostics10010039
dc.relation.publisherversionhttps://www.mdpi.com/2075-4418/10/1/39
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
10.3390-diagnostics10010039.pdf9.94 MBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons